Baxter Mislabeled Chemotherapy Device: FDA
On Tuesday, the FDA released a letter sent to Baxter on Sept. 10, in which the agency identified labeling and manufacturing issues related to one of the company's medical devices.
Baxter spokeswoman Mavis Prall said the letter referred to the company's Isolex device and the reagent kit used with the device. Isolex is used...
To view the full article, register now.